Sildenafil: Its Use as a PDE5 Inhibitor for Erectile Dysfunction
Phosphodiesterase type 5 (PDE5) inhibitors are first‑line oral agents for erectile dysfunction that augment the endogenous nitric oxide–cGMP pathway in the corpus cavernosum to facilitate erection with sexual stimulation, and the class includes sildenafil, vardenafil, tadalafil, and avanafil. Standard pharmacology texts detail shared mechanisms with clinically important differences in onset, duration, food effects, selectivity, and … Read more